Silo Pharma (SILO) revenue and earnings history
Silo Pharma reported revenue of $72K for fiscal 2025 (year ended Dec 31, 2025), 0.0% on the year before, and net income of −$4.23M.
Over 6 years, from fiscal 2019 to fiscal 2025, revenue grew at a compound rate of +10.1% a year.
Revenue and net income, 12 fiscal years
Annual figures, newest first
| Fiscal year | Revenue | Operating income | Net income | Operating cash flow | Capital expenditure | Free cash flow | Stock-based pay | Share buybacks | Dividends paid | Cash at year end | Total debt at year end | Report |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025ended Dec 31, 2025 | $72K0.0% | −$4.28M | −$4.23M | −$4.66M | — | — | $117K | — | — | $4.75M | — | 10-K |
| 2024ended Dec 31, 2024 |
The latest quarter, insider trades and fund moves: Silo Pharma (SILO) on OQRO.
Common questions
What was Silo Pharma's revenue in fiscal 2025?
$72K for the year ended Dec 31, 2025, as reported in its 10-K filed Mar 27, 2026. That is 0.0% on fiscal 2024 ($72K).
How fast has Silo Pharma's revenue grown?
From $41K in fiscal 2019 to $72K in fiscal 2025: a compound annual growth rate of +10.1% over 6 years. This is arithmetic on the filed figures and says nothing about the years ahead.
Has Silo Pharma been profitable?
It reported a net loss in 9 of the years shown (2011, 2012, 2018, 2019, 2020, 2022, 2023, 2024, 2025). The highest net income was $3.9M in fiscal 2021.
Where these figures come from
The SEC’s companyfacts data: every figure Silo Pharma tagged in XBRL in its annual and quarterly reports since 2009 (some reports carry a few earlier years as comparatives). For each fiscal year OQRO keeps the twelve-month totals from the annual report and the cash and debt at year end, and when a later report restates a year, the later figure. Read again whenever the company files.
Figures are as reported, in US dollars, with no adjustment for acquisitions, disposals or one-off items. Earnings per share are left out because a stock split changes them between reports. This page describes the past and is not investment advice. No language model wrote it.
